Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01805089 · ClinicalTrials.gov registry record · Early Phase 1
Melatonin Versus Placebo in Breast Cancer
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 95
- Enrollment target
NCT01805089 is a Early Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 95 participants.
The verdict
NCT01805089, a Early Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether melatonin taken every night can affect blood levels of estrogen or IGF (insulin-growth factor levels). Both IGF and estrogen are normally produced in the body and may influence breast cancer risk. Melatonin is also naturally produced in the body. Laboratory studies have shown that melatonin may decrease cancer growth and influence estrogen and IGF levels. Melatonin's effects on sleep, hot flashes, and mood will also be measured.
Interventions
- DRUG Melatonin 3 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01805089
The ClinicalTrials.gov registry entry for NCT01805089 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melatonin 3 mg is the first listed.
NCT01805089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01805089 about?
NCT01805089 is a clinical study titled "Melatonin Versus Placebo in Breast Cancer". The purpose of this research study is to determine whether melatonin taken every night can affect blood levels of estrogen or IGF (insulin-growth factor levels). Both IGF and estrogen are normally produced in the body and may influence breast cancer risk. Melatonin is also naturally produced in the ...
What is the current status of trial NCT01805089?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 95 participants. The study started on 2006-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT01805089?
The interventions under investigation include: Melatonin 3 mg (DRUG).
Who is sponsoring clinical trial NCT01805089?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.